TrialSpark, Inc. announced that it has received $372 million in its series D round of funding co-led by new investors, Andreessen Horowitz LLC, and Sanofi on June 26, 2024. The transaction included participation from new investors, SV Angel Growth I LP, a fund managed by SV Angel, FPV Ventures, LLC, returning investors, Sequoia Capital Operations LLC, Thrive Capital Management, LLC, Emerson Collective, LLC, and individual investor, Lachy Groom. As part of the transaction, Scott Kupor from Andreessen Horowitz LLC, Alfred Lin from Sequoia Capital Operations LLC will join the company board of director's.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
89.94 EUR | +0.09% | +2.65% | +0.20% |
06-27 | CAC40: caution prevails ahead of crucial deadlines | CF |
06-27 | CAC40: consolidates solo, OAT/Bund spread widens to 81Pb | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.20% | 120B | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- TrialSpark, Inc. announced that it has received $372 million in funding from a group of investors